Follow the Oncimmune Holdings plc stock price and the full directors' dealings record of the company, a listed equity based in United Kingdom. Shares are quoted on the UK market, under the authority of RNS (LSE). The latest transaction was disclosed on 11 November 2024 (Purchase). Among the most active insiders: Martin Gouldstone. All data is openly available.
9
Insider Decl.
n/a
Thresholds
€112,882
5 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
Buys €112,882n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
48,370 shares@ £0.2065100.0% of flowLondon Stock Exchange, AIMXRNS:4792314
9 of 9 declarations
About Oncimmune Holdings plc
Oncimmune Holdings plc is a biotechnology company focused on developing diagnostic tests for cancer. It specializes in identifying immune biomarkers to enhance cancer screening and treatment.